Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Insider: Agency Looks Carefully Inside for New CDER Head

This article was originally published in RPM Report

Executive Summary

FDA’s Center for Drug Evaluation & Research still doesn’t have a permanent director. The longer the search goes on, the more likely the candidate will come from inside.
Advertisement

Related Content

Woodcock to the Rescue: Is CDER Approving More Products?
Leads and Contacts
The New User Fee Rules: FDA Sacrifices Timeliness, Tries to Save Predictability
FDA's Outlook on the Drug Approval Drought
The Unsung Vytorin Victim: Primary-Care Marketing
Open Disputes at FDA Advisory Committees: Get Ready for Institutionalized Cacophony
The Implementer: How the Official Who Will Make FDAAA Work Views the New Law
Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
Talent Squeeze at FDA: Bad News for Drug Reviews, Good News for Merck?
Help Wanted: FDA Begins Search for New CDER Director

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel